Erratum: Regorafenib in Japanese patients with solid tumors: Phase i study of safety, efficacy, and pharmacokinetics (Investigational New Drugs DOI: DOI 10.1007/s10637-013-9953-8);Regorafenib in Japanese patients with solid tumors: Phase I study of safety, efficacy, and pharmacokinetics

Investigational New Drugs

Volumn 32, Issue 1, 2014, Pages 104-112

  Sunakawa, Yu ^a   Furuse, Junji ^b   Okusaka, Takuji ^c   Ikeda, Masafumi ^d   Nagashima, Fumio ^b   Ueno, Hideki ^c   Mitsunaga, Shuichi ^d   Hashizume, Kensei ^e   Ito, Yuichiro ^e   Sasaki, Yasutsuna ^f  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b KYORIN UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e BAYER YAKUHIN LTD   (Japan)

^f SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Japanese patients; Multikinase inhibitor; Regorafenib; Solid tumors

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASE; REGORAFENIB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BILE DUCT CARCINOMA; CARCINOID; CLINICAL ARTICLE; CONSTIPATION; DESQUAMATION; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GINGIVITIS; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; JAPANESE; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OPEN STUDY; PANCREAS ADENOCARCINOMA; PANCREATIC NEUROENDOCRINE TUMOR; PENIS CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; PULPITIS; RASH; RHEUMATIC POLYMYALGIA; SALIVARY GLAND TUMOR; SKIN DISEASE; SMALL INTESTINE CARCINOMA; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT TUMOR; VITAL SIGN; VOICE CHANGE; WEIGHT REDUCTION;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; TREATMENT OUTCOME;

EID: 84899121465     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0021-1     Document Type: Erratum

References (10)

1. Gotink KJ, Verheul HMW (2010) Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13:1-14
2. Porter AC, Vaillancourt RR (1998) Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17:1343-1352 (Pubitemid 28458404)
3. Udagawa T, Wood M (2010) Tumor-stromal cell interactions and opportunities for therapeutic intervention. Curr Opin Pharmacol 10:369-374
4. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245-255
5. Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, Christensen O (2012) A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658-2667
6. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Büchert M, Christensen O, Jeffers M, Heinig R, Boix O, Mross K (2012) Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 106:1722-1727
7. Eisen T, Joenssu H, Nathan P Harper P, Wojtukiewicz M, Nicholson S, Bahl A, Tomczak P, Wagner A, Quinn D (2011) Phase II trial of the oral multi kinase inhibitor regorafenib (BAY 73-4506) as first-line therapy in patients with metastatic or unresectable renal cell carcinoma (RCC). European Multidisciplinary Cancer Congress; 23-27 September 2011, Stockholm, Sweden (abstr. 7.141)
8. Bolondi L, Tak WY, Gasbarrini A, Santoro A, Colombo M, Lim HY, Mazzaferro V, Wiest R, Reig M, Bruix J (2011) Phase II safety study of the oral multikinase inhibitor regorafenib (BAY 73-4506) as second-line therapy in patients with hepatocellular carcinoma (HCC). European Multidisciplinary Cancer Congress; 23-27 September 2011, Stockholm, Sweden (abstr. 6.576)
9. Grothey A, Cutsem EV, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, for the CORRECT Study Group (2012) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312
10. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, on behalf of all GRID study investigators (2012) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295-302